Epilepsy

Brain Tumors

Brain tumors are one of the most lethal entities in human health. The are difficult to diagnose and treat. Types include:

  • Primary brain tumors – those that begin in the brain  –  occur in people of all ages, although they are more commonly seen in children and older adults.
  • Metastatic brain tumors – those that have spread to the brain from another organ in the body –  are more common in adults than in children.

Tumors can directly destroy brain cells. They can also damage cells by producing inflammation, placing pressure on other parts of the brain, and increasing pressure within the skull.

Neurologic complications are some of the most frequent and debilitating complications of cancer. These complications significantly affect how a person feels, thinks, remembers and acts.

What UCSD Offers

UC San Diego has assembled a team of world-renowned experts in neuro-oncology, neurosurgery and neuroimaging for the comprehensive research and treatment of brain tumors. These specialists have adapted the latest technology in diagnosing and treating brain tumors and its complications to improve treatment.

Researchers at UC San Diego are collaborating and applying personalized medicine to advance the treatments available for brain tumors. Through ongoing education and training opportunities, the team is working to develop the next generation of clinical specialists in brain tumor treatment and research.


Related Research Programs

Related Clinical Programs

Related Faculty

Related Clinical Trials

Enter the project number in the clinical trials search tool for more details.
  • Tasigna (Nilotinib) - 091728
  • Angiocept with or without Irinotecan (Campostar) – 100485
  • Notch Inhibitor (MK-0752) – 091642
  • Temodar (Temozolomide) with or without NovoCure device – 081483
  • Radiation Therapy with or without Temodar (temozolomide) - 091758
  • Radiation and Temodar with Avastin (bevacizumab) or placebo – 091437

Related Videos 
Brain 
About the UCSD Brain Tumor Program (with Neurosciences Chair William Mobley, Santosh Kesari and Bob Carter)